期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗Ⅰ型戈谢病新药他利苷酶-α的药理作用及临床评价 被引量：1

Pharmacological and clinical evaluation of taliglucerase alfa for the treatment of type 1 Gaucher's disease
原文传递
导出
摘要 他利苷酶-α(taliglucerase alfa)是一种利用基因重组技术在植物细胞中培养而成的β-葡糖脑苷脂酶类似物,2012年5月1日经FDA批准上市,用于治疗Ⅰ型戈谢病成年患者。本文对其药理作用、药代动力学、临床评价、安全性评价等方面进行综述。 Taliglucerase alfa is a plant-derived recombinant human glucocerebrosidase. Taliglucerase alfa was approved by FDA for the treatment of type 1 Gaucher＇s disease in adults on May 1st, 2012. The pharmacologi- cal action, pharmacokinetics, clinical trials and safety of taliglucerase alfa were reviewed in this paper.
作者 张爱玲 史爱欣 谢婧 胡欣
机构地区 沈阳药科大学药学院 卫生部北京医院药学部
出处 《中国新药杂志》 CAS CSCD 北大核心 2013年第3期253-255,259,共4页 Chinese Journal of New Drugs
关键词 他利苷酶-α Ⅰ型戈谢病 药理作用 药代动力学 临床评价 安全性评价 taliglucerase alfa type 1 Gaueher＇s disease pharmacology pharmaeokinetics clinical trails safety evaluation
分类号 R979.9 [医药卫生—药品]
  • 相关文献

参考文献16

  • 1GRABOWSKI GA. Phenotype, diagnosis, and treatment of Gaueher's disease[J].Lancet ,2008,372 (9645) :1263 - 1271.
  • 2段彦龙,张永红,臧晏,施惠平,张为民,胡亚美.酶替代治疗戈谢病72例[J].中华儿科杂志,2006,44(9):653-656. 被引量：34
  • 3REAVESN D. A model of effective health policy: the 1983 Or- phan Drug Act[J].JHealth Soc Policy, 2003,17(4) :61 -71.
  • 4BARTON NW, BRADY RO, DAMBROSIA JM, et al. Replace- ment therapy for inherited enzyme deficiency: macrophage-targe- ted glucocerebrosidase for Gaucher's disease[ J]. N Engl J Med, 1991, 324(21) :1464 - 1470.
  • 5TRAYNOR K. Taliglucerase alfa approved for Gaucher disease [J]. Am J Health Syst Pharm, 2012, 69(12):1009.
  • 6SHAALTIEL Y, BARTFELD D. Production of glucocerebrosi- dase with terminal mannose glycans for enzyme replacement thera- py of Gaucher's disease using a plant cell system[J]. Plant Bio- technol J, 2007, 5 (5) :579 - 590.
  • 7Prescribinginformation[ EB/OL]. [ 2012 - 05 - O1 ]. http ://www. accessdata, fda. gov/drugsatfda_docs/labe1/2012/O224581b1, pdf.
  • 8GINZBURG L, KACHER Y, FUTERMAN AH. The pathogenesis of glycosphingolipid storage disorders [ J ]. Semin Cell Dev Biol, 2004, 15(4) :417 -431.
  • 9ELLEDER M. Glucosylceramide transfer from lysosomes-the miss- ing link in molecular pathology of glucosylceramidase deficiency : a hypothesis based on existing data [ J ]. J Inherit Metab Dis, 2006, 29(6) :707 -715.
  • 10MORAN MT, SCHOFIELD JP, HAYMAN AR, et al. Pathologic gene expression in Guucher disease : up-regulation of cysteine pro- teinases including osteoclastic cathepsin[ J]. K Blood, 2000, 96 (5) :1969 - 1978.

二级参考文献14

  • 1胡亚美 江载芳 陆华 申昆玲 左启华 李同 等.实用儿科学(第7版)[M].北京:人民卫生出版社,2002.698-705.
  • 2Weinreb NJ,Charrow J,Andersson HC,et al.Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment:a report from the Gaucher Rigistry.Am J Med,2002,113:112-119.
  • 3Charrow J,Andersson HC,Kaplan P,et al.Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease:consensus recommendations.J Pediatr,2004,114:116.
  • 4Barton NW,Brady RO,Dambrosia JM,et al.Replacement therapy for inherited enzyme deficiency:Macrophage-targeted glucocerebrosidase for Gaucher's disease.N Engl J Med,1991,324:1464-1470.
  • 5Beutler E,Kay A,Saven A,et al.Enzyme replacement therapy for gaucher disease.Blood,1991,78:1183-1189.
  • 6Brady RO.Enzyme replacement therapy:conception,chaos and culmination.Phil Trans R Soc Lond B,2003,358:915-916.
  • 7Grabowski GA,Barton NW,Pastores G,et al.Enzyme therapy in type 1 Gaucher disease:comparative efficacy of mannose-terminated,glucocerebrosidase from natural and recombinant sources.Ann Intern Med,1995,122:33-39.
  • 8Pastores G,Sibille AR,Grabowski GA.Enzyme therapy in Gaucher disease type 1; dosage,efficasy,and adverse effects in 33 patients treated for 6 to 24 months.Blood,1993,82:408-416.
  • 9Grabowski GA,Leslie N,Wenstrup RJ.Enzyme therapy for Gaucher disease:the first 5 years.Blood Rev,1998,12:115-133.
  • 10Grabowski GA.Recent clinical progress in Gaucher disease.Curr Opin Pediatr,2005,17:519-524.

共引文献33

同被引文献7

  • 1Mullard A. 2012 FDA drug approvals[J]. Nat Rev Drug Discov, 2013, 12(2): 87-90.
  • 2Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy [J]. Engl J Med, 2012, 367(13): 1187-97.
  • 3美批准治HIV新药Stribild[EB/OL].(2012-08-28)[013-03-27].http://reahime.zaobao.com/2012/08/jgl20828_013.shtml.
  • 4JAK抑制剂[EB/OL].[2013-03-27].http://baike.baidu.com/view/9212190.htm.
  • 5Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib(CP-690,550) in combination with methotrex- ate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial[J]. Lancet, 2013, 381(9865): 451-60.
  • 6FDA批准瑞西巴库注射液治疗吸入性炭疽[EB/OL].(2013-02-04)[2013-03-27].http://cp.toocle.com/detail/6956511.html.
  • 7杨臻峥.抗结核药Bedaquiline[J].药学进展,2013,37(1). 被引量：5

引证文献1

二级引证文献2

中国新药杂志
2013年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部